key: cord-0813920-pbhggsh2
authors: Yang, Yu; Walls, Shannon D.; Gross, Stephen M.; Schroth, Gary P.; Jarman, Richard G.; Hang, Jun
title: Targeted Sequencing of Respiratory Viruses in Clinical Specimens for Pathogen Identification and Genome-Wide Analysis
date: 2018-05-12
journal: The Human Virome
DOI: 10.1007/978-1-4939-8682-8_10
sha: 7de08e540721065bcd2fd22009820e6b5da59fbe
doc_id: 813920
cord_uid: pbhggsh2

A large number of viruses can individually and concurrently cause various respiratory illnesses. Metagenomic sequencing using next-generation sequencing (NGS) technology is capable of identifying a variety of pathogens. Here, we describe a method using a large panel of oligo probes to enrich sequence targets of 34 respiratory DNA and RNA viruses that reduces non-viral reads in NGS data and achieves high performance of sequencing-based pathogen identification. The approach can be applied to total nucleic acids purified from respiratory swabs stored in viral transport medium. Illumina TruSeq RNA Access Library procedure is used in targeted sequencing of respiratory viruses. The samples are subjected to RNA fragmentation, random reverse transcription, random PCR amplification, and ligation with barcoded library adaptors. The libraries are pooled and subjected to two rounds of enrichments by using a large panel of oligos designed to capture whole genomes of 34 respiratory viruses. The enriched libraries are amplified and sequenced using Illumina MiSeq sequencing system and reagents. This method can achieve viral detection sensitivity comparable with molecular assay and obtain partial to complete genome sequences for each virus to allow accurate genotyping and variant analysis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this chapter (10.1007/978-1-4939-8682-8_10) contains supplementary material, which is available to authorized users.

In targeted DNA or RNA sequencing, a panel of oligonucleotide probes are used to capture nucleotide contents containing interested sequences, the enriched targets are sequenced using nextgeneration sequencing (NGS) to achieve sensitive detection and sequence-based analysis [1] . Several methods with comparable performance had been developed and successfully applied to sequencing of exomes, transcriptomes, cancer genes, significant pathogens, etc. [2] [3] [4] [5] [6] [7] [8] . Utilizing TruSeq RNA Access protocol and a large panel of oligos for whole-genome capture of 34 human respiratory viral pathogens (TruSeq RVP) enables enriching sequences of respiratory DNA and RNA viruses out of complex clinical specimens and production of genome sequences for genotyping and genetic variant analysis. The process includes collection, transportation, and storage of respiratory specimens, extraction of DNA and RNA, preparation of TruSeq fragment library, RVP enrichment, NGS and sequence data analysis (Fig. 1) . The laboratory procedures require approximately 5 days from specimens to NGS run excluding specimen acquisition, NGS instrument run time and post-run data processing and analyses. Fig. 1 Outline of the targeted sequencing of respiratory viruses in total nucleic acids from clinical specimens. The method uses TruSeq RNA Access Library Prep protocol and custom RVP oligos for genome-wide capture of 34 human respiratory viruses for next-generation sequencing (NGS)-based detections

The method is expected to detect all commonly known respiratory viral pathogens that are diagnosed with molecular tests such as Luminex xTAG RVP assay, FilmArray Respiratory Panel (RP) tests, multiplex real-time PCR tests for respiratory viral infection with comparable sensitivity and accuracy [9] [10] [11] . The large capture panel and the scheme of genome-wide capture allow detection of most known respiratory viruses and viruses with high sequence divergences. The method is robust in handling specimens with viruses of a wide range of concentrations as well as specimens of compromised quality, e.g., degraded nucleic acids or high nonviral contents. The high capture efficiency and the superior sensitivity from this method make it a powerful tool for discovery of respiratory virome. However, there is an elevated risk of false positivity which demands more stringent contamination control procedure for the investigation of clinical specimens (see Note 1).

Perform the procedures in a Biosafety Level 2 (BSL-2) laboratory with a certified biosafety cabinet (BSC). Use clinical specimens and agents that can cause infection within the biosafety cabinet.

Extract and purify DNA and RNA contents from respiratory swabs stored in a viral transport medium. Divide purified DNA/RNA into small aliquots, e.g., 10 μL per vial and store at −80 °C (see Note 2). 

Carry out all procedures at room temperature unless otherwise specified. Brief centrifugation or quick spin is done at 280 × g for 1 min in a benchtop centrifuge with microplate carriers for 96-well microplate or by a touch-spin using a microcentrifuge or a minicentrifuge for microcentrifuge tubes. Thaw frozen reagents at room temperature completely, vortex and centrifuge briefly, then keep them at room temperature or on ice until use. Immediately return all reagents to their original storage condition after use except for Resuspension Buffer which is kept at 4 °C after the initial use. 7) . Determine DNA concentration in ng/μL for each library. The expected size distribution for the library is 200−500 bp with apparent peak at approximately 260 bp (Fig. 2) . 5. During the incubation, prepare Pre-Mixed Elution in a microcentrifuge tube (to be used in 3.1.9. step 7): mix 28.5 μL of Enrichment Elution Buffer 1 and 1.5 μL of 2 N NaOH for each pool, and keep at room temperature until use.

6. Once the incubation is over, immediately remove the plate from the thermocycler and proceed to step 3.1.9.

1. Centrifuge the RAH1 plate, remove the seal, and transfer the first pool content to a clean 1.5 mL microcentrifuge tube labeled as S1, the second pool content to tube S2, and so on (see Note 9). Discard the RAH1 plate. Sequence the lib pool with PhiX control using Illumina MiSeq or NextSeq system. The acquired sequence data can be applied to bioinformatics data analysis pipeline, which may include data quality processing, the removal of human genome and transcriptome sequences, de novo assembly, and comparison of sequence contigs and unassembled reads with sequence databases using BLAST programs [12] (see Note 12). 6. The TruSeq RNA Access Library guide recommends using 10−100 ng of RNA as starting materials. Since total nucleic acids extracted from respiratory specimens contain both DNA and RNA and have highly variable concentrations from specimen to specimen, we use 8.5 μL of DNA/RNA for each sample in RNA fragmentation. 7 . Agilent 2100 Bioanalyzer can analyze up to 12 samples in one run. An alternative high-throughput system, the Agilent TapeStation 4200, can analyze up to 96 samples in one run.

8. The total hybridization time is about 2 h. Over hybridization may cause a high degree of nonspecific binding.

9. Instead of using microcentrifuge tubes and a magnetic beads separation rack, a 0.8 mL 96 deep well plate and a magnetic beads separation stand for 96-well plate can be used to process a large number of samples.

10. After two rounds of hybridization and capture and the second PCR amplification, the post-enrichment library appears having broadened size distribution with the peak shifted slightly to a higher molecular weight as compared with the fragment library shown in Fig. 2. 11. We always include Illumina PhiX Control v3 library in MiSeq runs. The PhiX control can be used for quick assessment of data quality and for technical trouble shooting. Besides, the addition of PhiX library can improve base calling quality for libraries with high G/C or A/T contents or low diversity sequences. The spiking ratio can be increased or reduced based on the needs and the nature of the specimens.

12. Using this method, partial to near-complete viral genome sequences can be obtained to allow genotyping and recombination and variant analysis. The method can detect both RNA and DNA viruses. During interpretation of the results, take cautious consideration of probable contamination and crosscontamination. If necessary, verify the results with additional tests such as molecular assays and/or by repeating the experiment with archived specimens or DNA/RNA aliquots.

those of the authors and do not reflect the official policy of the Department of the Army, Department of Defense or U.S. Government. We declare that no conflict of interest exists. This is the work of U.S. government employees and may not be copyrighted (17 USC 105).

Liquid-phase sequence capture and targeted re-sequencing revealed novel polymorphisms in tomato genes belonging to the MEP carotenoid pathway

Targeted enrichment for pathogen detection and characterization in three felid species

Enrichment of viral nucleic acids by solution hybrid selection with genus specific oligonucleotides

Performance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffin-embedded lung adenocarcinoma samples

Enhanced virome sequencing using targeted sequence capture

Virome capture sequencing enables sensitive viral diagnosis and comprehensive virome analysis

Development and evaluation of a panel of filovirus sequence capture probes for pathogen detection by next-generation sequencing

Evaluation of custom multiplex real -time RT -PCR in comparison to fast -track diagnostics respiratory 21 pathogens kit for detection of multiple respiratory viruses

Comparison of the conventional multiplex RT-PCR, real time RT-PCR and Luminex xTAG(R) RVP fast assay for the detection of respiratory viruses

Comparison of the Luminex xTAG RVP fast assay and the Idaho technology FilmArray RP assay for detection of respiratory viruses in pediatric patients at a cancer hospital

Pathosphere.org: pathogen detection and characterization through a web-based, open source informatics platform

We thank Darrell Dinwiddie for help in designing the RVP oligos. This work is supported by the Global Emerging Infections Surveillance and Response System (GEIS), a Division of the Armed Forces Health Surveillance Center. The views expressed here are